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The human parasite Toxoplasma gondii is sensitive to dinitroaniline compounds which selectively disrupt
microtubules in diverse protozoa but which have no detectable effect on vertebrate host cell microtubules or
other functions. Replication of wild-type T. gondii is inhibited by 0.5 to 2.5 M oryzalin, but mutant parasites
harboring amino acid substitutions in the predicted dinitroaniline binding site confer resistance up to 40 M
oryzalin. However, the precise interaction between dinitroanilines and the binding site in -tubulin remains
unclear. We have investigated the activity of 12 dinitroanilines and the related compound amiprophos methyl
on wild-type and dinitroaniline-resistant parasite lines that contain proposed binding site mutations. These
data indicate that dinitramine is the most effective dinitroaniline to inhibit Toxoplasma growth in wild-type
parasites and most resistant lines. Dinitramine has an amine group at the meta position not present in any of
the other dinitroanilines tested here that is predicted to form hydrogen bonds with residues Arg2 and Gln133
according to docking data. Remarkably, although the binding site mutation Ile235Val confers increased
resistance to most dinitroanilines, it confers increased sensitivity to GB-II-5, a compound optimized for activity
against kinetoplastid tubulin. Kinetoplastid parasites have a valine at position 235 of -tubulin, whereas
apicomplexan parasites have an isoleucine at this site. We suggest that this heterogeneity in binding site
environment influences relative dinitroaniline sensitivity in distinct protozoan lineages and hypothesize that a
mutation that makes the apicomplexan dinitroaniline binding site more like the kinetoplastid site increases
sensitivity to a dinitroaniline optimized for activity in the latter parasites.
Although tens of millions of people from the developing world
are impacted by diseases caused by parasitic protozoa, the efficacy
of available therapeutics is reduced by drug toxicity and the emer-
gence of drug-resistant parasite strains. The demand for new and
effective antiparasitic agents is immense. Since parasite microtu-
bules coordinate essential processes such as chromosome segre-
gation during mitosis, compounds that target protozoan but not
vertebrate host tubulin would act as parasite-specific antimitotic
agents. Dinitroaniline compounds exhibit this selective activity.
These small synthetic molecules (oryzalin, ethafluralin, trifluralin,
etc.) were discovered in 1960 by researchers looking to inhibit
land plant meristematic growth (1). In addition to activity in
plants, dinitroanilines disrupt microtubules in diverse protozoa,
including the free-living ciliate Tetrahymena thermophila and a
variety of protozoan parasites such as Leishmania spp., Trypano-
soma brucei, Trypanosoma cruzi, Entamoeba histolytica, Plasmo-
dium falciparum, Cryptosporidium parvum, and Toxoplasma gondii
(2–5, 8–10, 26, 28, 35–38, 40–42, 44–46, 55–59). These compounds
lack binding to and activity against vertebrate and fungal micro-
tubules (9, 26, 28, 44, 58). This selectivity is of interest for the
development of new antiparasitic agents.
Microtubules are essential components in eukaryotic cells,
forming diverse structures that coordinate cell movement, vesicle
transport, cell polarity, and mitosis (6, 11, 21–23, 29, 49). Many
protozoan parasites also contain plasma membrane-associated
microtubules that confer rigidity and a characteristic shape (24,
47). A typical microtubule is a cylindrical polymer formed by 13
longitudinal protofilaments (15, 16, 34). Each protofilament is
built by the head-to-tail linkage of --tubulin heterodimers. Mi-
crotubules exist in a dynamic equilibrium between tubulin dimer
subunits and microtubule polymers that is critical for proper func-
tion. Known antimitotic agents bind to specific sites on the tubulin
dimer to alter this equilibrium, making tubulin a well-established
target for diverse medical conditions ranging from cancer to hel-
minth infections (14, 30, 32, 57).
Both - and -tubulins are highly conserved among all eu-
karyotes (17, 39, 50). However, phylogenetic analysis of the
tubulin family has demonstrated that protozoan tubulins (from
Alveolates such as Tetrahymena, Plasmodium, and Toxoplasma
and from Euglenozoa such as Euglena, Trypanosoma, and
Leishmania) form a distinct group from vertebrate and fungal
tubulins, and these proteins are most similar to tubulins from
land plants (31). The amino acid sequences for -tubulins from
humans, apicomplexans (Toxoplasma gondii and Plasmodium
falciparum) and kinetoplastids (Trypanosoma cruzi and Leish-
mania major) share 83% identity. Conservation within major
groups is even higher: kinetoplastid and apicomplexan tubulins
are 86% identical and conservation among apicomplexans or
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among kinetoplastids is 93% (analysis not shown). Despite a
high degree of amino acid sequence conservation, some tubulin-
binding compounds are selectively active on phylogenetically
restricted tubulin subsets. For example, the benzimidazoles
oxfendazole and thiabendazole disrupt nematode and fungal mi-
crotubules without affecting human microtubules, making them
useful antihelminth and antifungal agents (12, 13, 20, 25, 32, 33,
52, 53). As described above, dinitroaniline compounds selec-
tively disrupt microtubules in diverse protozoa and plants
and lack binding to and activity against vertebrate and fun-
gal microtubules (reviewed in references 46, 56, and 57).
Computational data indicate that dinitroanilines bind to a
consensus site on protozoan -tubulin subunits (43, 45). Par-
allel studies with Bos taurus -tubulin show that dinitroanilines
do not interact with vertebrate tubulin (45). The binding site
on protozoan -tubulins is located under the H1-S2 (N) loop.
Since the H1-S2 loop is intimately associated with maintaining
protofilament contacts within the microtubule lattice, we hy-
pothesize that dinitroaniline binding interferes with this inter-
action to disrupt microtubules. Computational studies have
established that the dinitroaniline binding site is conserved
between apicomplexans (T. gondii and P. falciparum) and ki-
netoplastids (L. major) and that other dinitroaniline deriva-
tives (GB-II-5 and trifluralin) bind to the same site (43). How-
ever, distinct dinitroanilines possess different inhibitory effects.
Oryzalin inhibits T. gondii replication at 0.5 M, but is only
effective against Leishmania tubulin at 10 M (43). Structure
activity relationship (SAR) studies using oryzalin as the lead
compound have established that derivatives with altered func-
tional groups attached to the aniline nitrogen or the sulfon-
amide nitrogen are more active against kinetoplastid para-
sites (4, 5, 18, 19, 59, 60). The oryzalin derivative GB-II-5
(N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide) has
increased potency against kinetoplastids (T. brucei and
Leishmania spp.). However, it is much less efficient than
oryzalin against the apicomplexans P. falciparum and T.
gondii (N. Morrissette and K. Werbovetz, unpublished ob-
servations). Protozoan tubulin-dinitroaniline interactions
are likely to be influenced by minor species-specific differ-
ences in the properties of the binding site that alter inter-
actions with distinct functional groups on different dinitro-
aniline compounds.
In previous genetic studies of dinitroaniline resistance, we
identified and characterized a number of point mutations in
Toxoplasma 1-tubulin that confer resistance to oryzalin. A
subset of these mutations (Val4Leu, Ser6Ile, Phe24His,
His28Gln, Leu136Phe, Ile235Leu, Ile235Thr, Ile235Val,
Thr239Ile, Arg243Cys, and Arg243Ser) are located in the
computationally derived dinitroaniline binding site, and we
previously generated Toxoplasma lines harboring allelic replace-
ments of 1-tubulin with genes bearing each of these 11 point
mutations (35, 45). Eight of the substitutions (Val4Leu, Ser6Ile,
Phe24His, His28Gln, Leu136Phe, Thr239Ile, Arg243Cys, and
Arg243Ser) are within 4 Å of the bound dinitroaniline, indicating
a close association with the compound. Val4Leu, Leu136Phe,
Thr239Ile, and Arg243Ser confer higher resistance to oryzalin
(7.5 to 40 M) than the other point mutations identified so far,
suggesting that these positions may mediate more important di-
nitroaniline-ligand interactions. Finally, the 11 mutations are spa-
tially distributed around the dinitroaniline binding site, making
them a representative subset with which to study dinitroaniline
binding.
Dinitroanilines are important tools to elucidate the proper-
ties of selective -tubulin binding ligands. Optimization of
dinitroaniline site ligand activity requires a better understand-
ing of the interaction between tubulin and dinitroanilines. In
this study, we investigate the ability of dinitroanilines with
different functional groups to inhibit replication in both wild-
type parasites (RH strain) and in Toxoplasma lines with pre-
dicted binding site mutations. Dinitroaniline resistance is mea-
sured as the 50% inhibitory concentration (IC50) for each
Toxoplasma line. By assessing the effects of different dinitro-
anilines on wild-type and binding site mutants, we can identify
functional group-binding site interactions that will help us
identify improved lead compounds.
MATERIALS AND METHODS
Dinitroaniline compounds. Eleven commercially available dinitroaniline
compounds and the related phosphoric amide amiprophos-methyl (APM)
were obtained through Sigma-Aldrich: APM [O-methyl O-(2-nitro-p-tolyl)
N-isopropylphosphoramidothionate] was synthesized by Fluka; butralin (N-sec-
butyl-4-tert-butyl-2,6-dinitroaniline), dinitramine (N1,N1-diethyl-2,6-dinitro-4-triflu-
oromethyl-m-phenylenediamine), nitralin (4-mesyl-2,6-dinitro-N,N-dipropylaniline),
oryzalin (3,5-dinitro-N4,N4-dipropylsulfanilamide), pendimethalin [N-(1-ethylpro-
pyl)-2,6-dinitro-3,4-xylidine], and profluralin (N-cyclopropylmethyl-2,6-dinitro-N-




propalin (4-isopropyl-2,6-dinitro-N,N-dipropylaniline), and trifluralin (,,-
trifluoro-2,6-dinitro-N,N-dipropyl-p-toluidine) were synthesized by Sepulco.
GB-II-5 (N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide) was synthesized as
previously described (5).
Culture of Toxoplasma lines. T. gondii tachyzoites (the wild-type RH strain
and mutants derived from the RH strain) were grown in human foreskin
fibroblast (HFF) cells in DMEM with 10% fetal bovine serum (FBS) as
previously described (35, 36, 45). We previously generated T. gondii lines
bearing allelic replacements of point mutations Val4Leu, Ser6Ile, Phe24His,
His28Gln, Leu136Phe, Ile235Leu, Ile235Thr, Ile235Val, Thr239Ile,
Arg243Cys, and Arg243Ser in the 1-tubulin gene that are predicted to fall in
the computationally derived dinitroaniline binding site (35, 45). Lines bearing
oryzalin resistance mutations were propagated in media containing 0.5 M
oryzalin to prevent the appearance of revertants or suppressor mutations.
Determination of IC50 values. Inhibition of parasite growth in dinitroanili-
nes was measured by a plaque assay modified from a previously established
method (51, 54). Parasites were propagated in HFF cells in DMEM with 10%
(FBS). After complete lysis from HFF cells, extracellular parasites were
purified from host cell debris by passing lysate through a 3-m filter (GE
Osmonics). Confluent HFF cells in T25 flasks were exposed to culture media
that contain a specified concentration of each compound. Equivalent num-
bers of parasites (1,000) were inoculated into each flask, and these were left
undisturbed for 8 days at 37°C in a humidified 5% CO2 incubator. On the
eighth day, each T25 flask was rinsed once with phosphate-buffered saline
(PBS), and the remaining host cells were fixed with methanol (5 min at room
temperature) and stained with 5 crystal violet solution for 5 min. The crystal
violet staining solution consists of 12.5 g crystal violet in 125 ml ethanol mixed
with 500 ml 1% ammonium oxalate in H2O. After removal of the crystal violet
solution, cells were rinsed with PBS twice and allowed to air dry overnight.
Plaques (visualized as irregular clear areas against the violet background
produced by the HFF cells) were enumerated for each flask. To generate the
kill curve, plaque numbers (represented as a percentage of plaques relative to
the no drug control) were plotted versus drug concentration. The IC50 value
was extrapolated from the curve as the concentration in which there are 50%
of the total plaques compared to the control flask. The results represent the
average of three independent IC50 assays  standard error of the mean.
Immunofluorescence staining. HFF cells on 12-mm circular glass coverslips
were inoculated with RH parasites, and these samples were grown overnight
in specific dinitroanilines. Intracellular parasites were fixed, permeabilized,
and stained as previously described (48). The T. gondii surface was labeled
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with the anti-SAG1 antibody DG52 (7) and detected with an Alexa 594
secondary antibody (Invitrogen), while parasite microtubules were labeled
with a Toxoplasma-specific antitubulin antibody (48) detected with an Alexa
488 secondary antibody (Invitrogen). DNA was visualized by DAPI (4,6-
diamidino-2-phenylindole) staining (Vector Laboratories). Images were col-
lected on a Zeiss Axioskop using the Axiovision camera and software and
exported for manipulation in Photoshop 8.0.
Computational studies. We previously developed a homology model for Toxo-
plasma -tubulin and had performed molecular dynamics simulations using this
structure (43, 45). Representative structures taken every 50 ps from the 2.5-ns
trajectory were used with FRED (OpenEye Scientific Software, Santa Fe, NM)
to carry out flexible docking of dinitramine, trifluralin, and oryzalin onto each
snapshot. The results were analyzed for the specificity and types of interactions
(e.g., van der Waals and hydrogen bonding interactions) as well as common
positioning of each compound in the binding site.
RESULTS
Wild-type Toxoplasma strains display different sensitivities for
distinct dinitroanilines. In previous studies, we used morpho-
logical criteria to determine the oryzalin sensitivity of wild-type
and dinitroaniline-resistant Toxoplasma parasites, including
parasites that have amino acid substitutions in the computa-
tionally determined binding site. Assays that measure relative
growth of Toxoplasma in drug by direct proliferation measure-
ments are complicated by the fact that dinitroanilines inhibit
replication and invasion by parasite progeny but do not inhibit
metabolic activity of parasites in host cells (54). Although
plaques in plaque assays become smaller as compound con-
centrations are increased, we have adapted this standard assay
to determine IC50 values for 11 structurally distinct dinitro-
aniline compounds and two related compounds (GB-ll-5 and
APM) (Fig. 1 and 2). We have also validated that these com-
pounds act on Toxoplasma microtubules rather than by some
alternative means of toxicity using immunofluorescence mi-
croscopy to visualize tubulin in treated cells (Fig. 3). Wild-type
Toxoplasma tachyzoites treated with dinitramine have dis-
rupted microtubules, inhibited replication, and rounded cell
shape, in contrast to elongated and replicating parasites in
FIG. 1. Structure of the 12 dinitroaniline derivatives and the related phosphoric amide APM used in this study. The numbers represent the following
compounds. Compound 1 is the phosphoric amide amiprophos-methyl (APM). Compounds 2 to 13 are the following dinitroanilines: 2, benfluralin; 3, butralin;
4, dinitramine; 5, ethalfluralin; 6, fluchloralin; 7, GB-II-5; 8, isopropalin; 9, nitralin; 10, oryzalin; 11, pendimethalin; 12, profluralin; and 13, trifluralin.
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matched no-drug controls, consistent with previous observa-
tions (48). The IC50 data indicate that in wild-type parasites
dinitramine is the most effective derivative with an IC50 value
of 0.045 M (Table 1). The next most effective compounds are
oryzalin, pendimethalin, and ethalfluralin, which have 5-fold
higher IC50 values of 0.25 M. The least effective compound
is GB-ll-5, which has an IC50 value of 6.7 M.
Dinitramine is predicted to form an additional hydrogen
bond with tubulin. Dinitramine has significantly higher activity
in the IC50 plaque assay and is distinct from the other dini-
troanilines because it has an amine (NH2) group at the meta
position of the dinitroaniline. In all other compounds save
pendimethalin, which has a methyl (CH3) group at the meta
position, the dinitroanilines are unmodified at this site. In
computational studies, dinitramine appears to interact with
tubulin, with a similar orientation to the dinitroanilines oryza-
lin and trifluralin (Fig. 4A). However, docking analysis sug-
gests that the interaction of dinitramine with Toxoplasma -tu-
bulin is strengthened by the addition of two hydrogen bonds
which occur between the dinitramine NH2 and the backbone
carbonyl of Arg2 and the side-chain carbonyl of Gln133 (Fig.
4B). This reinforces other hydrogen bonds which are predicted
to form between the dinitramine NO2 and NH2 groups from
Val4 and Arg243, which also exist in other tubulin-dinitroani-
line interactions (Fig. 4).
Binding site mutations confer increased resistance to dini-
troanilines. We determined IC50 values for all of the com-
pounds in a set of parasite lines with allelic replacements of
each of the 11 1-tubulin point mutations that are located
within the computationally determined binding site. Our pre-
vious work established that the binding site mutations
Leu136Phe, Thr239Ile, and Arg243Ser conferred high levels of
oryzalin resistance (40 M) relative to other point mutations
(35). IC50 values from the current study confirmed this and
established that these mutations conferred high resistance to
all compounds tested in the current study, including dinitra-
mine and pendimethalin (Table 1). In addition to these three
high resistance mutations, Val4Leu increased IC50 values (7
M) to most compounds tested, with the exception of APM
(2.1 M), dinitramine (3.4 M), and pendimethalin (3.2 M).
Finally, the Phe24His and His28Gln mutations conferred
higher IC50 values (10 M) to a specific subset of com-
pounds. Parasites bearing the Phe24His mutation had IC50
values of 24.2 M for butralin, 17.2 M for GB-II-5, 15.7 M
for benfluralin, and 10.0 M for APM but the remaining com-
pounds had concentrations under 4.4 M in this assay. Para-
sites bearing the His28Gln mutation conferred an IC50 value of
15.2 M for benfluralin, 12.4 M for GB-II-5, and 10.2 M for
butralin but had IC50 values under 5.4 M for all remaining
compounds.
Dinitroaniline efficacy against binding site mutants. For the
11 binding site mutant lines, dinitramine was the most effective
dinitroaniline for 7 mutant lines (Ser6Ile, Phe24His, His28Gln,
Ile235Leu, Ile235Thr, Ile235Val, and Arg243Cys) and the sec-
ond most effective compound for the Val4Leu line (after
APM). Pendimethalin ranked first for two binding site mutant
lines (Arg243Ser and Thr239Ile) and was the second most
FIG. 2. Determination of IC50 values for a representative analysis. (A) Representative kill curves for R243S parasites. The individual curves
(F, }, and Œ) represent three independent plaque assays for R243S parasites in profluralin. (B and C) Crystal violet-stained flasks for the control
(B) and 20 M concentration of profluralin (C). As the concentration of dinitroaniline increases, plaques become less frequent and smaller in size.
FIG. 3. Intracellular Toxoplasma stained with a Toxoplasma-spe-
cific antitubulin antibody (green), a surface antigen (SAG-1; red), and
DNA labeled with DAPI (blue) indicates that the dinitramine disrupts
parasite microtubules. Immunofluorescent images (A and C) and
phase-contrast microscopy (B, D) of control parasites (A and B) and
parasites treated with 0.25 M dinitramine (C and D) illustrate that
the characteristic crescent shape of tachyzoites is converted into a
round and nondividing morphology (arrows) typical of parasites with
disrupted microtubules. Scale bar, 10 m.
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effective compound for 6 mutant lines (Val4Leu, Ser6Ile,
Ile235Leu, Ile235Thr, Ile235Val, and Arg243Cys). Overall,
ranking drug efficacy against Toxoplasma lines with binding
site mutations shows that dinitramine and pendimethalin
are the most and second most effective compounds against
binding site mutant lines, consistent with their efficacy
against wild-type parasites. In contrast, APM, benfluralin,
butralin, and GB-II-5 routinely rank among the least effec-
tive compounds against both binding site mutants and wild-
type parasites.
As the least effective compound overall, GB-II-5 had a
higher IC50 range: from 5 to 30 M for all binding site
mutant parasites tested with one exception. Toxoplasma
tachyzoites bearing the resistance mutation Ile235Val have
increased sensitivity to GB-II-5 (Fig. 5A). In wild-type para-
sites, the IC50 value is 6.7 M, whereas it is 4.7 M for the
Ile235Val line. As described above, GB-II-5 is a modified di-
nitroaniline with increased efficacy in kinetoplastid parasites
that shows decreased activity in apicomplexans. It is the only
compound with a bulky functional group at the position cor-
responding to the oryzalin sulfonamide. An alignment of -tu-
bulins from the apicomplexans Toxoplasma gondii (1) and
Plasmodium falciparum (1) and the kinetoplastid parasites
Leishmania major and Trypanosoma brucei shows that the
binding site residue at 235 is an isoleucine in apicomplexans
and a valine in the kinetoplastids (Fig. 5B). The Ile/Val dis-
tinction is present in a larger number of kinetoplastid and
apicomplexan tubulins. A QVIS sequence is conserved in api-
complexan -tubulins from C. parvum, Cryptosporidium homi-
nis, Cryptosporidium muris, Plasmodium berghei, Plasmodium
chabaudi, Plasmodium knowlesi, Plasmodium vivax, Plasmo-
dium yoelli, and P. falciparum, while the QVVS sequence is
conserved in the kinetoplastids Leishmania braziliensis, Leish-
mania chagasi, Leishmania infantum, L. major, Leishmania do-
novani, Leishmania tarentolae, T. brucei, T. cruzi, Trypanosoma
grayi, and Trypanosoma cyclops. The resistance mutation
Ile235Val makes the Toxoplasma binding site more similar to
the kinetoplastid site, perhaps explaining why this resistance
mutant has increased sensitivity to GB-II-5 relative to wild-
type parasites. We also investigated the activity of GB-II-5
against Toxoplasma lines with the oryzalin-resistant 1-tubulin
mutations Asn139Lys, Val252Leu, Met268Thr, Ile275Thr,
Ala295Val, and Met391Ile since these resistance mutations are
in residues where there are differences between apicomplexan
and kinetoplastid -tubulins. In three of the cases, the resis-
tance mutation corresponds to the distinct kinetoplastid amino
acid (Leu252, Val295, and Ile391), and in three other cases
there is a different amino acid at this site (His139, Val268, and
Val275). None of these mutations maps to the dinitroaniline
binding site, and in all cases, these mutations were not associ-
ated with increased GB-II-5 sensitivity (data not shown).
DISCUSSION
A number of studies have shown that microtubules in pro-
tozoan parasites are sensitive to dinitroaniline compounds
(2–5, 8–10, 26, 28, 35–38, 40–42, 44–46, 55–59). SAR studies by
several groups indicated that modification of functional groups
on dinitroanilines can increase antitubulin activity in specific
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ralin precursor chloralin established that both NO2 moieties are
critical to inhibit Leishmania promastigotes, as substitutions to
groups with less electron-withdrawing activity correspond to loss
of antileishmania activity (8). Studies of inhibition of the apicom-
plexan C. parvum demonstrated that substitution for the aniline
propyl chains of oryzalin and trifluralin with two cyclohexanes or
one phenyl group retains the antiparasitic activity, but substitu-
tions that increase hydrophilicity of dinitroanilines decrease com-
pound efficacy against parasites (3, 8, 41). More recent work on
the relationship between derivatives and kinetoplastid tubulin has
optimized activity for the kinetoplastids Leishmania and Trypano-
soma (4, 5, 18, 19, 59). Oryzalin is only moderately effective
against kinetoplastids, but its derivative GB-II-5 disrupts Leish-
mania microtubules more efficiently. However, as described
above, there is a reciprocal relationship between efficacy of oryza-
lin and GB-II-5: while GB-II-5 has increased potency over oryza-
lin in kinetoplastids, it has decreased activity on apicomplexans
which are sensitive to oryzalin.
This study characterizes nine compounds with asymmetrical
structures (APM, benfluralin, butralin, dinitramine, ethalflura-
lin, GB-II-5, fluchloralin, pendimethalin, and profluralin) and
four symmetrical dinitroanilines (isopropalin, nitralin, oryza-
lin, and trifluralin). Dinitramine and pendimethalin were the
most effective compounds against both wild-type parasites and
mutants harboring binding site substitutions. Both compounds
feature an additional functional group at the meta position
(NH2 for dinitramine and CH3 for pendimethalin), suggesting
that functionalizing this position augments dinitroaniline bind-
ing to -tubulin. The dinitroaniline prodiamine also has a meta
NH2 (like dinitramine) but like oryzalin possesses two propyl
chains at the aniline nitrogen (dinitramine has two ethyl
chains). Although we obtained a prodiamine solution to verify
that the additional NH2 group is responsible for the enhanced
efficacy of dinitramine as compared to oryzalin, its insolubility
in aqueous solution made it impossible to test in a biological
setting. Nonetheless, the fact that dinitramine is more potent
than all other compounds indicates that the addition of a
hydrogen bond donor like NH2 might strengthen the dinitro-
aniline-tubulin interaction. Indeed, the dinitramine NH2 is
predicted to provide additional hydrogen bonds by interacting
with the backbone carbonyl of Arg2 and the side-chain car-
bonyl of Gln133. However, addition of a nonpolar group like
CH3 still helps dinitroaniline binding, as evidenced by the
higher efficacy of pendimethalin than those of the remaining
compounds in this study. Pendimethalin might also be less
effective than dinitramine because it has only one alkyl chain
FIG. 4. Model of dinitramine docked to Toxoplasma -tubulin. Docking results for dinitroanilines on Toxoplasma -tubulin. (A) Common
docking orientation of oryzalin (orange), trifluralin (cyan), and dinitramine (yellow) in the binding cleft with amino acids within 3 Å of the docked
compounds shown in detail; (B) molecular details for dinitramine showing the two hydrogen-bonding interactions of the NH2 functional group with
the backbone carbonyl of Arg2 and the side-chain carbonyl of Gln133. The Arg243 residue is omitted so not to obscure the hydrogen-bonding
interactions of the dinitramine NH2 with Arg2 and Gln133 (dashed lines).
FIG. 5. (A) IC50 values for oryzalin and GB-II-5 in wild-type par-
asites and parasites bearing the Ile235Val mutation, which decreases
sensitivity to oryzalin but increases sensitivity to GB-II-5. The
Ile235Val line is significantly more sensitive to GB-II-5 than the wild
type (*, P  0.02; t test, single tail). (B) Partial alignment of the amino
acid sequences for -tubulin in the apicomplexans Toxoplasma gondii
(Tg) and Plasmodium falciparum (Pf) and the kinetoplastids Leishma-
nia major (Lm) and Trypanosoma brucei (Tb). The distinct amino acid
at position 235 is highlighted in gray. Toxoplasma carries three distinct
-tubulin genes. The alignment is shown for Toxoplasma 1-tubulin,
which appears to be the dominant tubulin; all Toxoplasma dinitroani-
line resistance mutations described to date are in the 1-tubulin gene
(35, 45, 46). The Val is conserved in 2-tubulin, but 3-tubulin has a
Leu at the corresponding position.
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instead of two at the aniline nitrogen. Butralin also has only
one alkyl chain at the same position, and APM does not con-
tain an analogous functional group. Both rank as the most
ineffective compounds for wild-type parasites and most binding
site mutant lines. Therefore, the presence of two alkyl chains at
the aniline nitrogen might stabilize dinitroaniline binding.
Overall, the improved efficacy of dinitramine and pendimetha-
lin over other dinitroaniline compounds suggests a novel site
for functionalizing dinitroanilines in future SAR studies, as
previous research focused only on modifying the nitro groups,
the aniline alkyl chains, or the location corresponding to oryza-
lin sulfonamide (2–5, 8, 18, 19, 41, 59, 60).
The IC50 values also suggest the relative contribution of
specific binding site residues to the interaction with dinitroa-
nilines. Mutations Leu136Phe, Thr239Ile, Arg243Ser, and
Val4Leu are especially important as they confer high resis-
tance relative to other point mutations to most compounds
tested, including dinitramine and pendimethalin. This obser-
vation suggests the importance of these substitutions for dis-
rupting the dinitroaniline-tubulin interaction in general. Pre-
vious studies of the computationally determined binding site
show that residues Val4, Leu136, Thr239, and Arg243 are
located along the same side of the binding site pocket, facing
the -tubulin core and away from the H1-S2 (N) loop (43).
Computational modeling has suggested an identically located
binding site for dinitroanilines in kinetoplastid and apicompl-
exan -tubulin. However, there are four amino acid differences
between the kinetoplastid and apicomplexan binding site res-
idues which might contribute to the differential efficacy of
specific dinitroanilines. The residues Val4, Thr41, Leu136, and
Ile235 in the apicomplexan site correspond to Ala4, Cys41,
Met136, and Val235 in the kinetoplastid site (Clustal align-
ment not shown) (27). Moreover, distinct residues outside of
the binding site could also influence properties of the binding
site. GB-II-5 is the least effective compound against wild-type
Toxoplasma parasites and binding site mutants. However, the
Toxoplasma line harboring the Ile235Val oryzalin resistance
mutation is more sensitive to GB-II-5 (IC50 value of 4.7 M)
than wild-type parasites (IC50 value of 6.7 M). The mutation
Ile235Val converts the apicomplexan residue into a kinetoplas-
tid residue, and this substitution makes GB-II-5 a more effective
compound in Toxoplasma. This observation suggests that species-
specific differences in tubulin might explain the differential effi-
cacy of dinitroanilines on apicomplexans and kinetoplastids.
Studies of the effect of dinitroaniline derivatives on the re-
lated apicomplexan C. parvum are largely consistent with the
data presented here. In a short-term in vitro culture assay,
fluchloralin, nitralin, oryzalin, pendimethalin, profluralin, and
trifluralin had IC50 values of 1.81, 4.5, 0.7, 0.19, 1.9, and 1.94
M (2, 3). Pendimethalin is one of the most effective com-
pounds in both Toxoplasma and Cryptosporidium, while triflu-
ralin and nitralin are much less effective in both organisms.
Profluralin is relatively more effective in Cryptosporidium than
Toxoplasma, while oryzalin is considerably more effective in
Toxoplasma. With the exception of pendimethalin, Toxoplasma
is apparently more sensitive to the dinitroaniline derivatives
than Cryptosporidium. Another possible explanation for differ-
ences in compound activity is that distinct functional groups on
different dinitroanilines may influence their relative concentra-
tions inside intracellular Toxoplasma and Cryptosporidium
rather than the direct interaction with tubulin. We are cur-
rently developing binding assays to test the direct interaction of
dinitroanilines with purified tubulin. Such assays will help re-
solve whether the effects of distinct functional groups are spe-
cific to tubulin binding or the nonspecific consequence of dif-
ferential compound access.
In sum, we have identified dinitramine as the most effective
compound in our current study of dinitroaniline derivatives.
The additional NH2 group at the meta position in dinitramine
is predicted to provide donors for additional hydrogen bonds,
which may explain its increased efficacy over other dinitroani-
lines. Additionally, the second most effective compound,
pendimethalin, also possesses an additional functional group at
the same position. Therefore, novel modifications in the meta
position of dinitroanilines represent a new strategy to function-
alize dinitroanilines and increase dinitroaniline efficacy.
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